NanoVibronix Posts Q3 Profit Amidst Merger, Reverse Splits, and Soaring Costs

TL;DR

**FEED's Q3 profit is a mirage; the company's still bleeding cash and facing a 'going concern' warning despite a merger and reverse splits.**

AI Summary

NanoVibronix, Inc. (FEED) reported a net income of $510 thousand for the three months ended September 30, 2025, a significant improvement from a net loss of $998 thousand in the same period of 2024. However, for the nine months ended September 30, 2025, the company still posted a net loss of $5.333 million, compared to a net loss of $2.274 million in the prior year. Revenue increased to $722 thousand for the three-month period in 2025 from $376 thousand in 2024, and to $2.241 million for the nine-month period in 2025 from $2.114 million in 2024. Gross profit decreased for the nine-month period to $523 thousand in 2025 from $1.225 million in 2024, despite the revenue increase, indicating higher cost of revenues. The company completed the ENvue Merger on February 14, 2025, and effected two reverse stock splits (1-for-11 in March 2025 and 1-for-10 in August 2025). Operating expenses surged to $8.598 million for the nine months ended September 30, 2025, from $3.437 million in the prior year, driven by increases in R&D, selling & marketing, and G&A. The company's cash and cash equivalents significantly increased to $6.950 million as of September 30, 2025, from $752 thousand at December 31, 2024, primarily due to $12.820 million in financing activities, including proceeds from stock issuance and tranche financing. Despite the improved quarterly net income, NanoVibronix continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows from operations, with an accumulated deficit of $76.858 million.

Why It Matters

This filing reveals NanoVibronix's aggressive strategic shifts, including the ENvue Merger and two reverse stock splits, which are critical for investors to understand the company's new direction and capital structure. While the Q3 2025 net income of $510 thousand is a positive sign, the substantial nine-month net loss of $5.333 million and the 'going concern' warning highlight significant financial instability. The surge in operating expenses, particularly in R&D and S&M, suggests a push for growth post-merger, but also raises questions about cost control and path to sustainable profitability. Competitively, the acquisition of ENvue Medical Holdings LLC positions NanoVibronix in the enteral feeding market, potentially diversifying its medical device portfolio, but also introduces new integration risks and market challenges.

Risk Assessment

Risk Level: high — NanoVibronix explicitly states 'These conditions raise substantial doubt about the Company's ability to continue as a going concern for twelve months from the date of issuance of these interim condensed consolidated financial statements.' This is supported by an accumulated deficit of $76.858 million as of September 30, 2025, and negative cash flow from operations of $6.696 million for the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider this a high-risk speculative play. While the Q3 net income is positive, the underlying 'going concern' warning and significant accumulated deficit suggest fundamental financial instability. Monitor future filings closely for sustained profitability and positive operational cash flow before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$2.241 million

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$510 thousand

eps

N/A

gross Margin

23.3%

cash Position

$6.950 million

revenue Growth

+6.0%

Key Numbers

• $510 — Net income (loss) for Q3 2025 (in thousands) (Improved from $(998) thousand in Q3 2024)
• $(5,333) — Net loss for nine months ended Sept 30, 2025 (in thousands) (Increased from $(2,274) thousand in the prior year period)
• $722 — Revenue for Q3 2025 (in thousands) (Increased from $376 thousand in Q3 2024)
• $2,241 — Revenue for nine months ended Sept 30, 2025 (in thousands) (Increased from $2,114 thousand in the prior year period)
• $6,950 — Cash and cash equivalents as of Sept 30, 2025 (in thousands) (Increased from $752 thousand at Dec 31, 2024)
• $76,858 — Accumulated deficit as of Sept 30, 2025 (in thousands) (Indicates significant historical losses)
• $(6,696) — Net cash used in operating activities for nine months ended Sept 30, 2025 (in thousands) (Highlights ongoing negative operational cash flow)
• $12,820 — Net cash provided by financing activities for nine months ended Sept 30, 2025 (in thousands) (Primary source of cash increase)
• 1-for-11 — March 2025 Reverse Stock Split ratio (Adjusted common stock shares)
• 1-for-10 — August 2025 Reverse Stock Split ratio (Adjusted common stock shares)

Key Players & Entities

• NanoVibronix, Inc. (company) — registrant
• ENvue Medical Holdings LLC (company) — acquired subsidiary
• NVEH Merger Sub, Inc. (company) — wholly-owned subsidiary of NVEH Merger Sub I, Inc.
• NVEH Merger Sub II, LLC (company) — wholly-owned subsidiary of NanoVibronix, Inc.
• Securities and Exchange Commission (regulator) — filing oversight
• Delaware (regulator) — state of incorporation
• NASDAQ Capital Market (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows from operations. As of September 30, 2025, the accumulated deficit was $76.858 million, underscoring significant historical unprofitability.
• Increased Operating Expenses [high — financial]: Operating expenses surged to $8.598 million for the nine months ended September 30, 2025, from $3.437 million in the prior year. This increase was driven by higher Research & Development, Selling & Marketing, and General & Administrative costs, impacting profitability.
• Decreased Gross Profit Margin [medium — financial]: Despite a revenue increase to $2.241 million for the nine months ended September 30, 2025, gross profit decreased to $523 thousand from $1.225 million in the prior year. This indicates a significant rise in the cost of revenues, eroding gross profitability.
• Dependence on Financing Activities [medium — financial]: The company's cash position increased to $6.950 million as of September 30, 2025, primarily due to $12.820 million in financing activities, including stock issuance and tranche financing. This highlights a reliance on external funding rather than operational cash generation.
• Merger Integration and Execution [medium — operational]: The completion of the ENvue Merger on February 14, 2025, introduces complexities in integrating operations, systems, and personnel. Successful execution is critical for realizing synergies and achieving strategic objectives.
• Impact of Reverse Stock Splits [low — financial]: The company effected two reverse stock splits (1-for-11 in March 2025 and 1-for-10 in August 2025). While intended to adjust share count, these splits can sometimes signal underlying financial challenges and may affect investor perception.

Industry Context

NanoVibronix operates in the medical device sector, specifically focusing on therapeutic devices. This industry is characterized by high R&D investment, stringent regulatory pathways (FDA approval), and a competitive landscape with both established players and innovative startups. Trends include increasing adoption of non-invasive therapies and digital health integration.

Regulatory Implications

As a medical device company, NanoVibronix is subject to rigorous regulatory oversight by bodies like the FDA. Compliance with manufacturing standards (e.g., GMP), product safety, and marketing regulations is paramount. Any failure to comply can result in significant penalties, product recalls, and reputational damage.

What Investors Should Do

1. Monitor Operating Expense Control
2. Analyze Revenue Quality and Gross Margins
3. Evaluate Going Concern Disclosure
4. Assess Impact of Financing Activities

Key Dates

• 2025-02-14: Completion of ENvue Merger — A significant strategic event that likely impacts the company's structure, operations, and financial reporting going forward.
• 2025-03-XX: 1-for-11 Reverse Stock Split — Adjusted the number of outstanding common shares, potentially to meet exchange listing requirements or improve per-share metrics.
• 2025-08-XX: 1-for-10 Reverse Stock Split — Further adjusted the number of outstanding common shares, continuing the trend from the earlier split.
• 2025-09-30: End of Third Quarter and Nine-Month Period — Reporting period for the financial data discussed, showing improved quarterly net income but continued net loss for the year-to-date.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, less any cumulative net income. It represents a deficit in retained earnings. (Indicates the company's long history of unprofitability, contributing to going concern doubts.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical disclosure for investors.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (The company executed two reverse stock splits in 2025, significantly altering its share structure.)

Tranche Financing

A method of financing where funds are disbursed in stages or 'tranches' rather than all at once, often tied to the achievement of specific milestones. (A source of cash inflow, indicating reliance on structured financing arrangements.)

Year-Over-Year Comparison

Compared to the prior year period, NanoVibronix shows a mixed financial picture. Revenue for the nine months ended September 30, 2025, increased slightly to $2.241 million from $2.114 million in 2024. However, gross profit significantly decreased to $523 thousand from $1.225 million, indicating higher costs. Operating expenses more than doubled to $8.598 million from $3.437 million, leading to a wider net loss for the nine-month period ($5.333 million vs. $2.274 million). Despite these challenges, cash reserves substantially improved due to financing activities.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share NAOV NASDAQ Capital Mark

Filing Documents

• form10-q.htm (10-Q) — 1222KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 14KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-25-023542.txt ( ) — 6734KB
• naov-20250930.xsd (EX-101.SCH) — 47KB
• naov-20250930_cal.xml (EX-101.CAL) — 60KB
• naov-20250930_def.xml (EX-101.DEF) — 250KB
• naov-20250930_lab.xml (EX-101.LAB) — 393KB
• naov-20250930_pre.xml (EX-101.PRE) — 334KB
• form10-q_htm.xml (XML) — 976KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited), and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025, and 2024 2 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025, and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025, and 2024 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 34

Signatures

Signatures 35 i PART I - FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NanoVibronix, Inc. Condensed Consolidated Balance Sheets (Unaudited) (Amounts in thousands except share and per share data) September 30, 2025 December 31, 2024 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 6,950 $ 752 Restricted cash 30 - Trade receivables 252 98 Prepaid expenses and other accounts receivable 540 290 Inventory 2,243 2,191 Total current assets 10,015 3,331 Noncurrent assets: Property and equipment, net 124 9 Long-term trade receivables 23 - Severance pay fund 190 173 Operating lease right-of-use assets 125 116 Intangible assets 5,275 - Goodwill 38,631 - Total non-current assets 44,368 298 Total assets $ 54,383 $ 3,629 LIABILITIES AND STOCKHOLDERS' EQUITY: Current liabilities: Trade payables $ 492 $ 47 Other accounts payable and accrued expenses 4,267 2,608 Loans 1,043 - Tranche financing liability 2,000 - Warranty liability 3,730 - Deferred revenue - 15 Operating lease liabilities, current 112 52 Total current liabilities 11,644 2,722 Non-current liabilities: Accrued severance pay 260 216 Operating lease liabilities, non-current 15 64 Total liabilities 11,919 3,002 Commitments and contingencies - - Stockholders' equity (*): Series G Preferred stock of $ 0.001 par value - Authorized: 400,000 and 0 shares at September 30, 2025 and December 31, 2024, respectively; Issued and outstanding: 820 and 0 shares at September 30, 2025 and December 31, 2024 - (*) - (*) Series X Preferred stock of $ 0.001 par value - Authorized: 62,220 and 0 shares at September 30, 2025 and December 31, 2024, respectively; Issued and outstanding: 53,100 and 0 shares at September 30, 2025 and December 31, 2024 (*) - - Series H Preferred stock of $ 0.001 par value - Authorized: 11,000 and 0 shares at September 30, 2025 an

View Full Filing

View this 10-Q filing on SEC EDGAR